Aspirin-Myocardial Infarction Study (AMIS)
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
To determine whether the daily administration of 1 gm of aspirin to individuals with a documented myocardial infarction would result in a significant reduction in mortality over a three year period.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Oct 1974
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 1974
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 1979
CompletedFirst Submitted
Initial submission to the registry
October 27, 1999
CompletedFirst Posted
Study publicly available on registry
October 28, 1999
CompletedMarch 25, 2016
April 1, 2012
October 27, 1999
March 24, 2016
Conditions
Interventions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Related Publications (13)
Aspirin Myocardial Infarction Research Group: A Study of Aspirin in Patients with Myocardial Infarction. Prostaglandins in Hematology. Spectrum Publications Inc, New York, l977, 36l-370.
BACKGROUNDAn intervention study-the aspirin myocardial infarction study. Lipids. 1977 Jan;12(1):59-63. doi: 10.1007/BF02532973.
PMID: 319319BACKGROUNDA randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980 Feb 15;243(7):661-9.
PMID: 6985998BACKGROUNDAspirin Myocardial Infarction Research Group: Aspirin Myocardial Infarction Study: Design, Methods and Baseline Results. DHEW Pub. No. (NIH) 80-2l06, l980.
BACKGROUNDThe aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. Circulation. 1980 Dec;62(6 Pt 2):V79-84.
PMID: 7438383BACKGROUNDWasserman AG, Bren GB, Ross AM, Richardson DW, Hutchinson RG, Rios JC. Prognostic implications of diagnostic Q waves after myocardial infarction. Circulation. 1982 Jun;65(7):1451-5. doi: 10.1161/01.cir.65.7.1451.
PMID: 7042113BACKGROUNDGoldstein S, Friedman L, Hutchinson R, Canner P, Romhilt D, Schlant R, Sobrino R, Verter J, Wasserman A. Timing, mechanism and clinical setting of witnessed deaths in postmyocardial infarction patients. J Am Coll Cardiol. 1984 May;3(5):1111-7. doi: 10.1016/s0735-1097(84)80167-9.
PMID: 6423716BACKGROUNDMattson ME, Curb JD, McArdle R. Participation in a clinical trial: the patients' point of view. Control Clin Trials. 1985 Jun;6(2):156-67. doi: 10.1016/0197-2456(85)90121-7.
PMID: 4006489BACKGROUNDShekelle RB, Gale M, Norusis M. Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study. Am J Cardiol. 1985 Aug 1;56(4):221-5. doi: 10.1016/0002-9149(85)90838-0.
PMID: 3895879BACKGROUNDFrost PH, Verter J, Miller D. Serum lipids and lipoproteins after myocardial infarction: associations with cardiovascular mortality and experience in the Aspirin Myocardial Infarction Study. Am Heart J. 1987 Jun;113(6):1356-64. doi: 10.1016/0002-8703(87)90648-x.
PMID: 3591604BACKGROUNDSchoenberger JA. Recruitment experience in the Aspirin Myocardial Infarction Study. Control Clin Trials. 1987 Dec;8(4 Suppl):74S-78S. doi: 10.1016/0197-2456(87)90009-2.
PMID: 3440392BACKGROUNDFurberg CD, Friedman LM, MacMahon SW: Women as Participants in Trials of the Primary and Secondary Prevention of Cardiovascular Disease: Part II. Secondary Prevention: The Beta-Blocker Heart Attack Trial and the Aspirin Myocardial Infarction Study, in: Coronary Heart Disease in Women. ED Eaker, B Packard, NK Wenger, TB Carkson, HA Tyroler (Eds). New York, Haymarket Doyma, pp 241-246, 1987.
BACKGROUNDHoward J, Whittemore AS, Hoover JJ, Panos M. How blind was the patient blind in AMIS? Clin Pharmacol Ther. 1982 Nov;32(5):543-53. doi: 10.1038/clpt.1982.201.
PMID: 7127995BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
Allan Barker
Salt Lake Clinic Research Foundation
David Berkson
Unity Health Toronto
William Berstein
Icahn School of Medicine at Mount Sinai
Nemat Borhani
University of California, Davis
Elmer Cooper
Santa Rosa Medical Center
Leonard Dreifus
Lankenau Hospital
Noble Fowler
University of Cincinnati
Phillip Frost
USPHS Hospital
Mario Garcia-Palmieri
University of Puerto Rico Medical Science Campus
Hugh Gilmore
University of Miami
Sidney Goldstein
Henry Ford Hospital
Olga Haring
Northwestern University
J. Hoover
University of Washington
Richard Hutchinson
University of Mississippi Medical Center
William Krol
University of Maryland at Baltimore
Peter Kuo
Rutgers Medical School
Charles, Laubach
Institute for Medical Education and Research
Bernard Lewis
Palo Alto Medical Research Foundation
Jessie Marmorston
University of Southern California
J. McNamara
Pacific Health Research Institute
Dayton Miller
U.S. Centers for Disease Control and Prevention
Thaddeus Prout
Greater Baltimore Medical Center
David Richardson
Virginia Commonwealth University
Jorge Rios
George Washington University
Paul Samuel
Long Island Jewish-Hillside Medical Center
Stephen Scheidt
Weill Medical College of Cornell University
Robert Schlant
Emory University
Henry Schoch
University of Michigan
James Schoenberger
Rush University Medical Center
Marvin Segal
MOUNT SINAI HOSPITAL
Pantel Vokonas
Boston Health and Hospitals Department
C. Williams
Ogden Research Foundation
Gary Wilner
Endeavor Health
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- PREVENTION
- Sponsor Type
- NIH
Study Record Dates
First Submitted
October 27, 1999
First Posted
October 28, 1999
Study Start
October 1, 1974
Study Completion
August 1, 1979
Last Updated
March 25, 2016
Record last verified: 2012-04